DE2522081C2 - - Google Patents
Info
- Publication number
- DE2522081C2 DE2522081C2 DE2522081A DE2522081A DE2522081C2 DE 2522081 C2 DE2522081 C2 DE 2522081C2 DE 2522081 A DE2522081 A DE 2522081A DE 2522081 A DE2522081 A DE 2522081A DE 2522081 C2 DE2522081 C2 DE 2522081C2
- Authority
- DE
- Germany
- Prior art keywords
- phosphonomycin
- combination
- dose
- mixing ratio
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 5
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 5
- 229960001139 cefazolin Drugs 0.000 claims description 4
- 229960002588 cefradine Drugs 0.000 claims description 4
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752522081 DE2522081A1 (de) | 1975-05-17 | 1975-05-17 | Antibiotisch wirksames praeparat |
| FR7614462A FR2311551A1 (fr) | 1975-05-17 | 1976-05-13 | Preparation antibiotique |
| BE166980A BE841775A (fr) | 1975-05-17 | 1976-05-13 | Preparation antibiotique |
| GB19800/76A GB1530017A (en) | 1975-05-17 | 1976-05-13 | Antibiotically active preparation |
| SE7605551A SE7605551L (sv) | 1975-05-17 | 1976-05-14 | Antibiotiskt verksamt preparat |
| IE1031/76A IE43373B1 (en) | 1975-05-17 | 1976-05-14 | Antibiotically active preparation |
| CA252,625A CA1068603A (en) | 1975-05-17 | 1976-05-14 | Preparations comprising phosphonomycin and another antibiotic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752522081 DE2522081A1 (de) | 1975-05-17 | 1975-05-17 | Antibiotisch wirksames praeparat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2522081A1 DE2522081A1 (de) | 1976-11-25 |
| DE2522081C2 true DE2522081C2 (enrdf_load_stackoverflow) | 1987-07-30 |
Family
ID=5946844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752522081 Granted DE2522081A1 (de) | 1975-05-17 | 1975-05-17 | Antibiotisch wirksames praeparat |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE841775A (enrdf_load_stackoverflow) |
| CA (1) | CA1068603A (enrdf_load_stackoverflow) |
| DE (1) | DE2522081A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2311551A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1530017A (enrdf_load_stackoverflow) |
| IE (1) | IE43373B1 (enrdf_load_stackoverflow) |
| SE (1) | SE7605551L (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
| DE102008046610A1 (de) * | 2008-09-09 | 2010-03-11 | Biomet Deutschland Gmbh | Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6814976A (enrdf_load_stackoverflow) * | 1968-05-15 | 1969-11-18 | ||
| DE1924205B2 (de) * | 1969-05-12 | 1973-01-04 | Rilco Maschinenfabrik Gmbh & Co Kg, 7407 Dusslingen | Druckmittelbetriebene Vorrichtung zur Erzeugung einer hin- und hergehenden Bewegung |
| US3678163A (en) * | 1969-06-02 | 1972-07-18 | Merck & Co Inc | Stabilized aqueous suspension of calcium (-) (cis-1,2-epoxypropyl)-phosphonate |
| FR2100969A2 (en) * | 1970-07-30 | 1972-03-24 | Merck & Co Inc | Antibiotic compns - contng (-) (cis-1,2-epoxypropyl) phosphonic acid |
-
1975
- 1975-05-17 DE DE19752522081 patent/DE2522081A1/de active Granted
-
1976
- 1976-05-13 GB GB19800/76A patent/GB1530017A/en not_active Expired
- 1976-05-13 BE BE166980A patent/BE841775A/xx not_active IP Right Cessation
- 1976-05-13 FR FR7614462A patent/FR2311551A1/fr active Granted
- 1976-05-14 CA CA252,625A patent/CA1068603A/en not_active Expired
- 1976-05-14 IE IE1031/76A patent/IE43373B1/en unknown
- 1976-05-14 SE SE7605551A patent/SE7605551L/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE841775A (fr) | 1976-09-01 |
| GB1530017A (en) | 1978-10-25 |
| IE43373L (en) | 1976-11-17 |
| SE7605551L (sv) | 1976-11-18 |
| CA1068603A (en) | 1979-12-25 |
| DE2522081A1 (de) | 1976-11-25 |
| FR2311551A1 (fr) | 1976-12-17 |
| IE43373B1 (en) | 1981-02-11 |
| FR2311551B1 (enrdf_load_stackoverflow) | 1978-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2250993C2 (de) | Antibakterielles Mittel | |
| EP0240829A2 (de) | Cancerostatisches Mittel | |
| DE69615984T2 (de) | Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen | |
| DE2522081C2 (enrdf_load_stackoverflow) | ||
| EP0398165A1 (de) | Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE3324964C2 (enrdf_load_stackoverflow) | ||
| DE2525064C2 (de) | Arzneimittel mit Antiparkinson-Wirkung | |
| DE202023001867U1 (de) | Formulierung umfassend mindestens eine Kresse-Art | |
| DE3852717T2 (de) | Zusammensetzung für die Prophylaxe von Pneumocystis-carinii-Pneumonie. | |
| DE2521922A1 (de) | Pharmazeutisches mittel | |
| DE3785953T2 (de) | Bakterientötende Gemische. | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
| DE2461570C3 (de) | Arzneimittel für die Behandlung bakterieller Infektionen der Augen und/oder der Ohren und Verfahren zu ihrer Herstellung | |
| DE2833014A1 (de) | Antibiotisch wirksames mittel | |
| EP0513400B1 (de) | Verwendung von 2-Ethoxybenzoesäure zur Herstellung eines Arzneimittels als Analgetikum, Antipyretikum und/oder Antiphlogistikum | |
| DE2445679A1 (de) | Neue immunitaets-stimulierende medikamente | |
| EP0672411B1 (de) | Verwendung von 2-Methylamino-2-phenylcyclohexanon zur Behandlung von Infektionen und zur Immunmodulation | |
| DE2633943A1 (de) | Oral oder parenteral zu verabreichende loesung eines oxazepins | |
| DE2721034C2 (enrdf_load_stackoverflow) | ||
| DE2150921C2 (de) | Chemotherapeutisch wirksame, zwei Wirkstoffe enthaltende Präparate | |
| DE2532180C2 (de) | Verwendung von Etozolin bei der Bekämpfung der Hypertonie | |
| DE3147959A1 (de) | Pharmazeutische zusammensetzung, die 1- 2-(3'-caroxypropionyl)oxyethyl -2-methyl-5-nitroimidazol als therapeutischen wirkstoff gegen erkrankungen enthaelt, die von anaeroben bakterien verursacht sind | |
| DE2259624C3 (de) | Antibakterielles Arzneimittel | |
| DE3934855A1 (de) | Antibakterielles synergistisches praeparat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |